Skip to main content

Russell Singleton, David Ludvigson, Bruce Huebner, Philip Huxley, Karen Vaccaro, Gary Fagan, Kevin Bankshas, Christopher Steffen, Bruce Stillman, Thomas Kelly, William Castell

Premium

Perlegen has hired Russell Singleton as vice president for engineering and informatics. Previously, he was president of his own company, developing business and marketing strategies for early-stage biotechnology firms and semiconductor equipment companies. He also held several positions at KLA-Tencor. Prior to that, he led instrumentation and software development programs at Molecular Dynamics. Singleton holds a PhD and a master’s degree from the University of Illinois and a bachelor’s degree from the Pratt Institute.


David Ludvigson has been prom-oted to president and COO of Nanogen, the San Diego-based company said last week. He replaces Bruce Huebner, who resigned “to pursue other interests,” and will stay with the company for a transition period of several months. Ludvigson is currently Nanogen’s executive vice president and CFO. Ludvigson holds an MS and a BS degree from the University of Illinois in Champaign-Urbana.


Philip Huxley has become senior director of drug discovery at Galapagos Genomics, the Mechelen, Belgium-based company said last week. He joins the company from Avidex in Abingdon, UK, where he was head of drug discovery. Huxley obtained a PhD in theoretical chemistry from the University of Sussex in Brighton, UK.


Karen Vaccaro will retire as vice president for research and development of Matritech on June 25, the Newton, Mass.-based company said last week. She will continue to advise the company in the future. While Matritech is searching for a successor, Gary Fagan, senior director for product development, will become acting CSO.


Kevin Bankshas is the new vice president for business development at Geospiza, the Seattle-based bioinformatics company said. Prior to joining Geospiza, he worked for a number of informatics companies, including ImageX.com and Microsoft. Banks holds a doctorate in biophysical chemistry.


Christopher Steffen has joined the board of directors of Accelrys, the company said last week. He was vice-chairman and director of Citicorp until he retired in 1996.


Bruce Stillman and Thomas Kelly have jointly received the annual Alfred P. Sloan, Jr. Prize, General Motors said. They share the $250,000 award, one of three prizes given annually by the General Motors Cancer Research Foundation, for their contributions to the understanding of DNA replications in eukaryotes. Stillman is the president and CEO of Cold Spring Harbor Laboratory in New York. He holds a bachelor’s degree from the University of Sydney and a doctorate from Australian National University. Kelly is the director of the Sloan-Kettering Institute in New York City. He received a bachelor’s degree, an MD, and a PhD from Johns Hopkins University.


William Castell has become vice chairman of the board of directors of General Electric, the company said last week. He became president and CEO of GE Healthcare in April, following GE’s acquisition of Amersham, which he joined as CEO in 1989. He holds a BA in business studies from the City of London College.

 

Filed under

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.